{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'eTrack study number and', '201112 (EPI-NTHI-001 BOD APA)', 'Abbreviated Title', 'Date of protocol amendment', 'Amendment 3 Final: 19 October 2018', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort', 'study to assess the occurrence of potential bacterial', 'and viral pathogens in stable chronic obstructive', 'pulmonary disease (COPD) and during acute', 'exacerbations of COPD (AECOPD), in moderate to', 'very severe COPD patients, in Asia Pacific.', 'Investigator name', 'Signature', 'Date', 'For internal use only', 'Checksum-', '!Ver.!Created On -', '-', '15661ebdab2e949f7alflbc2071b9dec72acecef2.0 10/25/2018 6:16:52 PM - -', '19-OCT-2018', '6', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Sponsor Information', 'Sponsor', 'GlaxoSmithKline Biologicals', \"Rue de l'Institut 89\", '1330 Rixensart, Belgium', 'Sponsor Medical Expert for the Study', 'Refer to the local study contact information document.', 'Sponsor Study Monitor', 'Refer to the local study contact information document.', 'Study Contact for Reporting of a Serious Adverse Event (SAE)', 'GSK Biologicals Central Back-up Study Contact for Reporting SAEs: refer to protocol', 'Section 7.3.2.', 'Study Contact for Reporting SAEs: refer to the local study contact information', 'document.', '19-OCT-2018', '7', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'SYNOPSIS', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort study to', 'assess the occurrence of potential bacterial and viral', 'pathogens in stable chronic obstructive pulmonary disease', '(COPD) and during acute exacerbations of COPD', '(AECOPD), in moderate to very severe COPD patients, in', 'Asia Pacific.', 'Objectives', 'Primary', 'To estimate the proportion of potential bacterial and viral', 'pathogens (overall and by species) detected in sputum of', 'stable COPD patients and during AECOPD, using', 'respectively bacteriological methods and viral PCR, over the', 'course of 1 year.', 'Secondary', 'To evaluate the concordance between PCR and', 'bacteriological methods data in sputum for potential', 'bacterial pathogens.', 'To estimate the proportion of potential bacterial and viral', 'pathogens (overall and by species) detected in sputum of', 'stable COPD patients, by GOLD grade.', 'To estimate the proportion of potential bacterial and viral', 'pathogens (overall and by species) detected in sputum', 'during AECOPD, by severity of AECOPD.', 'To estimate the incidence rate of all-cause AECOPD,', 'overall and by GOLD grade.', 'To describe the severity and duration of all-cause', 'AECOPD, overall and by GOLD grade.', 'To assess the impact of all-cause AECOPD on HRQOL.', 'To assess the impact of all-cause AECOPD on lung', 'function.', 'To assess the impact of all-cause AECOPD on healthcare', 'utilisation.', '19-OCT-2018', '8', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}